Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC grew its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 6.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 931,894 shares of the medical device company's stock after buying an additional 58,920 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned 1.42% of Tandem Diabetes Care worth $33,567,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Hood River Capital Management LLC purchased a new stake in shares of Tandem Diabetes Care in the 4th quarter worth approximately $46,035,000. Baillie Gifford & Co. lifted its holdings in Tandem Diabetes Care by 235.7% during the fourth quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after buying an additional 523,843 shares during the period. GW&K Investment Management LLC boosted its position in Tandem Diabetes Care by 18.0% during the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after acquiring an additional 323,674 shares in the last quarter. Stephens Investment Management Group LLC increased its holdings in shares of Tandem Diabetes Care by 22.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock valued at $56,040,000 after acquiring an additional 281,327 shares during the period. Finally, Barclays PLC raised its position in shares of Tandem Diabetes Care by 106.4% in the 4th quarter. Barclays PLC now owns 476,974 shares of the medical device company's stock worth $17,180,000 after acquiring an additional 245,909 shares in the last quarter.

Tandem Diabetes Care Price Performance

TNDM traded down $0.70 during trading on Tuesday, reaching $16.77. The company's stock had a trading volume of 1,916,818 shares, compared to its average volume of 1,505,085. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The firm has a fifty day simple moving average of $19.89 and a two-hundred day simple moving average of $29.03. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -8.69 and a beta of 1.52. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on TNDM shares. Canaccord Genuity Group reiterated a "buy" rating and issued a $63.00 target price on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Citigroup downgraded Tandem Diabetes Care from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $35.00 to $24.00 in a research report on Tuesday, March 4th. Barclays lowered their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Royal Bank of Canada lowered their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, Tandem Diabetes Care has a consensus rating of "Moderate Buy" and an average price target of $43.81.

Insider Buying and Selling at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos bought 10,538 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 1.90% of the stock is owned by company insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.